uniQure submits FDA BLA for accelerated approval for Huntington’s gene therapy

 

uniQure submits FDA BLA for accelerated approval and UK MHRA MAA for Huntington’s gene therapy ifezuntirgene inilparvovec (AMT-130)

• William Blair resumed coverage of uniQure with Outperform rating and $73 fair value, citing AMT-130 filings.

https://finviz.com/stock?t=QURE&p=d